Edition:
United Kingdom

Reckitt Benckiser Group PLC (RB.L)

RB.L on London Stock Exchange

6,220.00GBp
5:00pm BST
Change (% chg)

-48.00 (-0.77%)
Prev Close
6,268.00
Open
6,233.00
Day's High
6,325.00
Day's Low
6,218.00
Volume
1,230,909
Avg. Vol
1,223,081
52-wk High
7,174.00
52-wk Low
5,559.00

Select another date:

Tue, Jul 30 2019

Photo

Reckitt cuts sales target as China infant formula demand slows

LONDON Reckitt Benckiser cut its full-year revenue target after reporting lower than expected sales in its last quarter under long-time chief executive Rakesh Kapoor, hurt by a surprise slowdown in demand for infant formula in China.

Reckitt cuts sales target as China infant formula demand slows

LONDON Reckitt Benckiser cut its full-year revenue target after reporting lower than expected sales in its last quarter under long-time chief executive Rakesh Kapoor, hurt by a surprise slowdown in demand for infant formula in China.

UPDATE 4-Reckitt cuts sales target as China infant formula demand slows

* Health unit posts surprise sales drop due to China slowdown

BP surge lifts FTSE 100 to 11-mth high; Centrica slumps

July 30 A surge in oil major BP offset steep losses in consumer goods giant Reckitt Benckiser and energy utility Centrica and lifted London's FTSE 100 to a fresh 11-month high on Tuesday.

Reckitt Benckiser sales miss as China infant formula demand falls

LONDON, July 30 British household goods maker Reckitt Benckiser reported worse than expected second-quarter sales, hurt by a slowdown in demand for infant formula in the United States and China, its biggest market.

Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

Reckitt Benckiser has agreed to pay up to $1.4 billion to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment. | Video

Indivior says Reckitt settlement in U.S. unrelated to its cases

Drugmaker Indivior Plc said on Thursday its former parent Reckitt Benckiser's $1.4 billion settlement with authorities in the United States was separate to its ongoing legal proceedings.

Reckitt to pay $1.4 billion to end U.S. opioid addiction treatment probes

Reckitt Benckiser has agreed to pay up to $1.4 billion (£1.1 billion) to resolve U.S. claims that its former pharmaceuticals business Indivior before it was spun out of the company carried out an illegal scheme to boost sales of an opioid addiction treatment. | Video

UPDATE 6-Reckitt to pay $1.4 bln to end U.S. opioid addiction treatment probes

* RB shares rise as much as 3.3% (Recasts with details from Justice Department settlement announcement)

Indivior says Reckitt settlement in U.S. unrelated to its cases

Drugmaker Indivior Plc said on Thursday its former parent Reckitt Benckiser's $1.4 billion settlement with authorities in the United States was separate to its ongoing legal proceedings.

Select another date: